Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback